Anti -idiotype antibody, 1A7, functionally mimics the tumor -associated antigen disialoganglioside GD2, which is overexpressed on the surface of a number of neuroectodermal tumors such as melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung. Immunization of mice with 1A7 generated the production of anti -GD2 antibodies. In a phase I clinical trial, immunization of patients with 1A7, mixed with the adjuvant QS21, demonstrated that 1A7 could act as a surrogate antigen for GD2 and induce strong humoral immune responses in advanced stage melanoma patients. DNA vaccines have recently been shown to invoke humoral as well as cellular responses in injected hosts against the transgene product. To evaluate the efficiency of DNA vaccines encoding anti -idiotype antibodies, we constructed expression plasmids encoding the variable heavy ( VH ) and variable light ( VL ) chains of 1A7. The plasmids were made in two configurations, expressing either the VH ( pc1A7VHLnVL ) or the VL ( pc1A7VLLnVH ) chain of 1A7 at the amino terminus, linked together by a 15 -amino acid linker ( Ln ) . In vitro transcription / translation assays and transfection of CHO -K1 cells with the plasmids demonstrated that a $30 -kDa protein was expressed by both configurations of the single -chain variable fragment. This protein can be specifically precipitated by monoclonal anti -GD2 antibody, 14G2a. Following intramuscular injection in mice, the plasmids were detectable in the injected tissues for at least 3 months and the injected plasmids actively transcribed the single -chain variable fragment 1A7 gene at the injected site. A single, intramuscular immunization of a group of C57BL / 6 mice with pc1A7VLLnVH in phosphate -buffered saline induced humoral immune responses against 1A7 as well as GD2, the nominal antigen. Multiple immunizations, however, were required to elicit stronger immune responses.
I
ncreased and aberrant membrane expression of different gangliosides, such as GD2, on tumors of neuroectodermal origin including malignant melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of lung tumor has been reported. 1 GD2 is absent in most normal tissues, except for low levels in brain and peripheral nerve. Thus, GD2 is an excellent target for immunotherapy of tumors of neuroectodermal origin, such as melanoma ( reviewed in Ref.
2 ). Although vaccination of cancer patients with different gangliosides has been tested by a number of investigators, 3, 4 GD2 is weakly immunogenic in humans. 5, 6 Other limitations of using GD2 as a cancer vaccine include the requirement of the covalent linkage of ganglioside to keyhole limpet hemocyanine, co -injection of a strong adjuvant, and, most important of all, the complex purification steps of these glycospingolipids.
As an alternate to purified ganglioside, we have chosen to use surrogate molecules. Our immunization strategy is based on the immune network concept of Jerne. 7 According to this concept, immunization with an antibody (Ab1 ) against an antigen can generate several types of antiidiotype antibodies (Ab2 ) in the injected host. One set of these anti -idiotype antibodies, designated Ab2, acts as the internal image of the antigen and mimics its molecular features. Thus, injection of Ab2 to the new host will elicit a new set of antibodies, which, besides binding to the Ab2 molecule ( Ab3 response) , will also bind to the nominal antigen (Ab1 H response ). The efficacy of antiidiotype antibodies as cancer vaccines has been demonstrated in a number of preclinical and clinical studies ( reviewed in Ref. 8 ).
We have generated a number of anti -idiotype antibodies for active, specific immunotherapy of different cancer patients. 9 ± 12 One of our anti -idiotype antibodies, designated 1A7, 12 mimics GD2. Immunization of small animals and nonhuman primates with 1A7 induced strong anti -1A7 as well as anti-GD2 humoral responses in the injected hosts.
12
1A7 mixed with the adjuvant QS -21 has also been used to immunize advanced stage melanoma patients. 13 All patients in this study demonstrated strong anti -1A7 antibody responses. Isotype analysis showed that these antibodies were mostly IgG and specifically bound to 1A7 (Ab3 response) as well as disialoganglioside GD2 (Ab1 H response) . These results demonstrated that a significant immune response against GD2 can be mounted and immunological tolerance against GD2 can be broken in melanoma patients by vaccination with an anti -idiotype antibody.
Although the injection of 1A7 invoked a strong humoral immune response against GD2, the presumed cellular immune responses could not be detected. Various plasmid constructs have been reported to invoke combined humoral and cellular immune responses against the encoded genes ( reviewed in Ref. 14 ) . To explore the feasibility of using DNA vaccines encoding anti -idiotype antibodies, we developed plasmids expressing the 1A7 single -chain variable fragment (scFv ) as a new generation of anti -idiotype vaccines.
ScFv consisting of a single variable heavy (VH ) and variable light (VL ) chain domain is the smallest antibody fragment capable of binding to an antigen. 15, 16 In this communication, we report the construction of two antiidiotype DNA vaccines, designated pc1A7VHLnVL and pc1A7VLLnVH, encoding two different configurations of the scFv of 1A7. We present results demonstrating that scFvs of 1A7 encoded by these plasmids are expressed in vitro and in vivo and the expressed protein can bind to the monoclonal Ab1 antibody, 14G2a. Moreover, our results demonstrate that a single intramuscular injection of these DNA vaccines, without any adjuvant or cytokines, induced anti -1A7 as well as anti-GD2 antibodies in the injected mice. However, multiple immunizations were required for induction of stronger immune responses.
MATERIALS AND METHODS

Materials
Monoclonal anti -GD2 antibody 14G2a ( IgG2a, ) was kindly provided by Dr. Reisfeld ( The Scripps Research Institute, La Jolla, CA ) . Plasmid pT7Blue (R ) and Nova blue ± competent cells were purchased from Novagen ( Madison, WI ) . pcDNA3 expression vector was obtained from Invitrogen ( Carlsbad, CA ). Columns for the purification of plasmids were from Qiagen (Valencia, CA ). CHO -KI cells were obtained from the American Type Culture Collection ( ATCC, Rockville, MD ) . DH5-competent cells were purchased from Life Technologies ( Gaithersburg, MD ) . Production of the control anti -idiotype antibody, 3H1, was described previously. 10 Antimouse IgG ( negative control monoclonal antibody ), biotinylated horseradish peroxidase ± conjugated goat antimouse IgG, Fcspecific alkaline phosphatase ± conjugated goat antimouse IgG, and all glycolipids were purchased from Sigma (St. Louis, MO ) . All restriction enzymes were obtained from Promega (Madison, WI ) and [
35 S ] L -methionine was from DuPont NEN (Boston, MA).
Generation of anti -idiotype antibody 1A7
The murine monoclonal IgG2a antiganglioside GD2 antibody 14G2a (Ab1 ) was used to immunize syngeneic BALB /c mice. Hybridoma fusion, cloning, and selection of the monoclonal anti -idiotype 1A7 ( Ab2 ) , as well as the production of ascites in bulk quantities in mice, were performed as described previously.
10 1A7 was purified from ascites by affinity chromatography on protein A -CL Sepharose 4B column, followed by diethylaminoethyl (DEAE) ion exchange chromatography. The purity of the isolated immunoglobulin ( >99% ) was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis ( SDS -PAGE ) , high -pressure liquid chromatography, and isoelectric focusing.
Molecular cloning of 1A7 and the determination of the sequence of cDNA encoding the VH and VL domains Total RNA was isolated by using the single -step procedure 17 from 1Â10 7 1A7 hybridoma cells. First strand cDNA was synthesized using a SuperScript Preamplification kit (Life Technologies ). DNA fragments encoding the VH of 1A7 were amplified by polymerase chain reaction ( PCR ) using the mixed oligonucleotide forward primer 5
H -ACTAGTC-GACATGGCTGTCYTRGSGCTRCTCTTCTGC and the reverse primer 5
H -CCCAAGCTTCCAGGGRCCARKGGA-TARACIGRTGG corresponding to sequences of the leader ( signal peptide) region amino acids À 12 to À 20 and the constant region amino acids 119± 126 of IgG. For the VL cDNA, the mixed oligonucleotide forward primer used was 5 H -ACTAGTCGACATGAAGTTGCCTGTTAGGCTGTTG-GTGCTG and the reverse primer was 5 H -CCCAAGCTT-ACTGGATGGTGGGAAGATGGA, corresponding respectively to À 10 to À 19 amino acids of the VL leader sequence and the 116 ±122 amino acids of the mouse constant region ( I= inosine, R =A or G, Y=C or T, S = C or G, K =G or T) . The amplified fragments of cDNA were subcloned into pT7Blue (R ) plasmid to obtain the two starting plasmids, pB1A7VH and pB1A7VL, respectively encoding the VH and VL of 1A7. Nova blue ± competent cells were transformed with pB1A7VH and pB1A7VL using the protocol supplied by the manufacturer ( Novagen ). Plasmids from selected clones were prepared by the miniprep procedure and the DNA sequence of the double -stranded plasmid was determined by Sequenase, version 2.0 kit from United States Biochemical (Cleveland, OH ). The DNA sequence was determined from both orientations using T7 promoter primer (5 H -TAATACGACTCACTATAGGG ) and U19 primer (5 H -GTTTTCCCAGTCACGACGT ) . To determine the entire sequence of the amplified cDNA fragments, oligonucleotides were synthesized corresponding to the sequences of the 5 H and 3 H ends of the sequence obtained in the first round and were used for a second round of sequencing.
Verification of the cDNA clone by amino acid sequence
For the amino acid sequence determination of 1A7 variable regions, 50 g of purified 1A7 was diluted with sample loading buffer (50 mM Tris ±HCl, pH 6.8, 1% SDS, 1% glycerol, 0.1% -mercaptoethanol ) and heated to 1008C for 3 minutes. The denatured protein was loaded onto a 7.5% polyacrylamide gel ( Bio -Rad Miniprotean II Dual Slab Cell ) containing SDS and subjected to electrophoresis at 200 V for 1 hour. Proteins in the gel were transferred to polyvinylidene difluoride membranes at 30 mA overnight. The transfer buffer contained 25 mM Tris ±192 mM glycine and 20% ( vol /vol ) methanol. The membranes were stained by quick dipping in 0.1% Coommassie Brilliant Blue (Sigma) in 50% methanol /50% acetic acid, followed by washing in a solution containing 40% methanol plus 10% acetic acid. After drying the membranes at room temperature, the stained VH and VL chain bands were excised with a clean razor blade. Proteins on the membrane slices were subjected to N -terminal microsequencing by automated Edman degradation using an Applied Biosystem Model 477A protein sequencer using pulsed liquid chemistry and online phenyl -ethiohydantoin amino acid identification. Each protein was subjected to 10 ± 15 degradative cycles and converted cleavage products from each cycle were analyzed by reverse-phase high -pressure liquid chromatography.
Construction of 1A7 scFv expression plasmids in two configurations
cDNAs of VH and VL chains of 1A7 were amplified from pB1A7VH and pB1A7VL, respectively, by PCR. For the VH chain, the forward primer (P1 ) was 5
H -GCCGATATCAC-CATGGCTGTCTTGGGGCTGCTC and the reverse primer ( P2) was 5 H -CATCTCTAGATTATGAGGAGACGGTGAC-TGAGGT. EcoRV and XbaI restriction sites were incorporated into those primers. The start codon at the 5 H end of the forward primer ( bold ) and the stop codon at the 3 H end of the reverse primer ( bold ) were also included. For VL chain, the forward primer (P3 ) was 5 H -GCCGATATCACCATG-GAGTTGCCTGTTAGGCTG and the reverse primer (P4 ) was 5
H -CATCTCTAGATTATTTGATTTCCAGCTTGGTG-CC. EcoRV and XbaI restriction sites (italics ) and start and stop codons were also incorporated in these two primers. cDNAs for VH and VL were linked together by a 15 -amino acid linker (Ln ), (Gly 4 Ser ) 3 . In order to get two different configurations of scFv, two different sets of Ln primers were synthesized. The forward primer for VH ±VL configuration ( P5) was 5 H -TCAGTCACCGTCTCCTCAGGGGGAGG-TGGCTCGGGCGGTGGCGGCTCG GGTGGCGGCGG-ATCCGATGTTTTGATGACCCAA. The reverse primer ( P6) was 5
H -TTGGGTCATCAAAACATCGGATCCGC-CGCCACCCGAGCCGCCACCGCCCGAGCCACCTCC-CCCTGAGGAGACGGTGACTGA. The 5 H end of the forward primer contained nucleotides corresponding to the 3 H end of the VH chain and the 3 H end of the Ln contained nucleotides corresponding to the 5 H end of the VL chain ( bold ). The forward primer for VL ± VH configurations ( P7) was 5
H -GGCACCAAGCTGGAAATCAAAGGGG-GAGGTGGCTCGGGCGGTGGCGGCTCGGGTGGCGG-CGGATCCCAGGTGCAGGTGAAGGAGTCA and the reverse primer (P8 ) was 5
H -TGACTCCTTCACCTGCAC CTGGGATCCGCCGCCACCCGAGCCGCCACCGCCC-GAGCCACCTCCCCCTTTGATTTCCAGCTTGGTGC-C. The two sets of primers, P5 and P6, were boiled for 10 minutes, cooled to room temperature, and subjected to PCR with VH and VL as templates. To obtain the plasmid of VH ± VL configuration, P1 and P4 were also added to the PCR reaction mixture. Similarly, for the VL ±VH configuration, primers P3 and P2 were used. The PCR products $800 bp were purified with QIAquick PCR purification Kit ( Qiagen ).
Construction of 1A7 scFv expression vectors
PCR products of VHLnVL and VLLnVH of 1A7 and pcDNA3 were digested with EcoRV and XbaI and were run on the 0.8% low melting point agarose gel at 10 mA for 4 hours. Expected bands were cut out from the gel with a razor and DNA fragments were purified using the GELase Agarose Gel Digestion Preparation according to the protocol of the manufacturer (Epicentre, Madison, WI ) . The EcoRVand XbaI -digested pcDNA3 and VHLnVL or VLLnVH of scFv were then ligated with T4 DNA Ligase (Promega ) by incubating at 168C overnight. The recombinant plasmids, pc1A7VHLnVL and pc1A7VLLnVH, were used for the transformation of DH5-competent cells ( Life Technologies ). Small-and large-scale plasmid purifications were performed by using appropriate Qiagen purification kits.
In vitro transcription and translation of pc1A7VHLnVL and pc1A7VLLnVH
pc1A7VHLnVL and pc1A7VLLnVH (1 g each ) were incubated with 40 L of TNT T7 Quick Master Mix ( TNT T7 Quick -Coupled Transcription / Translation System, Promega ) and with 10 Ci of [
35 S ] L -methionine for 1 hour at 308C. Five -microliter aliquots from the reaction mixture were mixed with 10 L of sample loading buffer (50 mM Tris ± HCl, pH 6.8, 1% SDS, 1% glycerol ) and were run on the 12% SDS -PAGE gel for 1 hour at 30 mA. After fixing the gel in 30% methanol / 10% acetic acid solution for 30 minutes, the gel was rinsed with water for 30 minutes and dried in a gel drier ( Bio -Rad, model 583) at 808C for 2 hours. Dried gels were exposed to KODAK X -OMAT AR film (Eastman Kodak, Rochester, NY) for autoradiography.
Transfection of CHO -K1 cells with pc1A7VHLnVL and pc1A7VLLnVH
CHO -K1 cells (2Â10 5 ) were plated on six -well Falcon plates overnight in 1 mL Dulbecco's Modified Eagle Medium containing 10% fetal calf serum. The cells were transfected with 2 g of plasmid plus 20 L Lipofectamine ( Life Technologies ) according to the manufacturer's protocol. After 36 hours at 378C in a tissue culture incubator, 20 Ci of [
35 S ] L -methionine was added to the media. The supernatant was collected after 5 hours and a 300-L aliquot was incubated with 2 g of either 14G2a, 3H1 (negative control anti -idiotype antibody ), or antimouse IgG ( negative control monoclonal antibody ) for 4 hours. Antigen ± antibody complexes were precipitated by incuba-tion with Protein A Sepharose 4 Fast Flow gel (Pharmacia Biotech, Piscataway, NJ ) for 4 hours at 48C followed by thorough wash with phosphate -buffered saline ( PBS ) . The precipitates were finally resuspended in 10 L sample loading buffer (50 mM Tris ±HCl, pH 6.8, 1% SDS, 1% glycerol ) for gel electrophoresis. All samples were run on the 12% SDS -PAGE for 1 hour at 30 mA and the gel was processed and autoradiographed as described above for in vitro transcription translation assay.
Transcription of pc1A7VLLnVH in mice
Fifty micrograms of pc1A7VLLnVH was injected into the leg quadriceps of C57BL /6 mice. At different intervals, the mice were sacrificed and muscle tissues removed. Total RNA from the muscle was obtained by Trizol reagent ( Life Technologies ) according to the manufacturer's protocol. The RNA was incubated with RNase -free bovine pancreatic DNase I ( Amersham Pharmacia Biotech, Piscataway, NJ ) , followed by reverse transcription (RT ) PCR using a kit ( TITAN One Tube RT-PCR System, Boehringer-Mannheim, Indianapolis, IN ) . The forward primer was 5
H -GCCGATATCACCATGGAG TTGCCTGTTAGGCTG and the reverse primer was 5
H -CATCTCTAGATTATGAGGA-GACGGTGACTGAGGT. Ten microliters of RT-PCR products was digested with KpnI and electrophoresed on a 1% agarose gel for 1 hour at 10 mA. Following electrophoresis, the gel was depurinated with 0.25 N HCl, denatured with 0.5 N NaOH ±1.5 M NaCl, and neutralized with 1.5 M NaCl, 0.1 M Tris pH 7.5. DNA from the gel was transferred to nitrocellulose membrane using Strategene ( La Jolla, CA ) PosiBlot Pressure Blotter and Pressure Control Station in 20Â SSC as transfer buffer (3 M NaCl ±0.3 M sodium citrate, pH, 7.0 ). The transfer was carried out for 1 hour at 75 mm Hg pressure and DNA on the membrane was cross -linked by UV. The probe, 32 P -labeled pc1A7VLLnVH, was prepared by using Random Primer DNA Labeling Kit according to the manufacturer's ( Life Technologies ) protocol. The membrane was incubated with prehybridization solution ( 6Â SSC, 5Â Denhardt's reagent, 0.5% SDS, 100 g denatured, fragmented salmon sperm DNA, 50% formamide) at 428C for 4 hours in a hybridization oven. 18 The prehybridization solution was discarded and the membrane was incubated with prewarmed hybridization solution ( 6Â SSC, 5Â Denhardt's reagent, 0.5% SDS, 100 g denatured, fragmented salmon sperm DNA, 50% formamide containing the 32 P -labeled pc1A7VLLnVH probe at 428C for 16 hours in the hybridization oven. The membrane was washed with increasing stringency of SSC ±SDS, as follows; 2Â SSC ± 0.5% SDS, 15 min; 2Â SSC ±0.1% SDS, 15 min; 0.1Â SSC ± 0.5% SDS, 30 min; and 0.1Â SSC for 5 min. The wet membrane was wrapped with saran wrap and exposed to Xray film ( KODAK -XAR -2, Eastman Kodak) for autoradiography.
Immunohistochemistry of muscle tissues after injection of DNA vaccines
Fifty micrograms of pc1A7VLLnVH was injected into leg quadriceps of C57BL /6 mice. After 7 days, the muscle tissue was removed, fixed in formalin, and embedded in paraffin.
The specimens were sliced into 4-m sections. Following fixation with xylene for 15 minutes, the sample was rehydrated by treatment with ethanol /methanol. The endogenous peroxidase activity was quenched by treatment with 0.3% hydrogen peroxide for 30 minutes. The tissue was treated with 10% goat serum in PBS for 30 minutes to block nonspecific antibody binding. After five washes with PBS, the tissue was incubated with the primary antibodies (14G2a, 3H1 in PBS ) or 1% bovine serum albumin (BSA ) in PBS for 90 min. The slides were washed with PBS (five times ) and incubated with biotinylated goat antimouse IgG for 60 minutes. After thorough washing with PBS, the tissue was treated with peroxidase -conjugated streptavidin for 30 minutes at room temperature. The slides were developed by incubation with AEC substrate kit for horseradish peroxidase (Vector Laboratories, Burlingame, CA ) and counterstained with hematoxylin for 10 minutes.
Immunization of mice with DNA vaccines
Four groups of 4± 6-week -old C57BL /6 female mice were injected with 100 g of purified plasmids into two leg quadriceps (50 g /leg ) . Group 1 was injected only once with pc1A7VLLnVH. The other three groups were immunized every other week for four times with: group 2, pcDNA; group 3, pc1A7VLLnVH; and group 4, pc1A7VHLnVL. Sera were drawn before each immunization and stored at À 208C for enzyme -linked immunosorbent assay ( ELISA ) .
Pepsin digestion of anti -idiotype antibody 1A7 into F ( ab ) 2 and Fc fragments Ten milligrams of 1A7 was digested with pepsin and F( ab ) 2 fragment was purified from Sepharose A column by using ImmunePure F ( ab) 2 Preparation Kit (Pierce Chemicals, Rockford, IL ) according to the manufacturer's protocol.
Assay for induction of anti -1A7 ( Ab3 ) response
The 96 -well Falcon plates were coated with 50 L of 5 g/ mL of 1A7 F (ab ) 2 in carbonate ±bicarbonate buffer, pH 9.6, overnight. After blocking with 3% BSA in PBS, the plates were incubated for 16 hours with 50 L of 1:10 diluted mouse sera. Plates were washed seven times with PBS containing 0.05% Tween -20 and incubated with 50 L of diluted Fc-specific alkaline phosphatase ±conjugated goat antimouse IgG for 2 hours. After washing, the color was developed with alkaline phosphatase substrate and the OD was read at 405 nm.
Assay of induction of anti -GD2 antibodies ( Ab1
H response )
samples and Ab1 monoclonal antibody, 14G2a, were diluted 1:10 with PBS ± BSA and 100 L was added in triplicate wells. After 4 hours of incubation at room temperature with shaking, the plates were washed with PBS. Bound antibodies were detected by treatment with alkaline phosphatase ± conjugated goat antimouse immunoglobulin, followed by the color reaction. Readings were taken at 405 nm in an ELISA reader.
T -cell proliferation assays
Mice (three in each group ) were immunized with pc1A7VHLnVL or pc1A7VLLnVH as described above. Spleens were isolated from the mice and pooled in PBS under sterile conditions. After smashing the spleen in PBS, the cell suspension was washed three times with 10 mL of RPMI 1640 medium, containing 10% fetal calf serum, by centrifugation at 1000Âg for 10 minutes. In each well of a 96-well Falcon plate, 2Â10 5 spleen cells were added and mixed gently with the stimulants ( 10 ng, 500 ng, 1 g, 1.5 g, or 2 g/ well ). Stimulants tested were anti -idiotype antibody 1A7, control anti -idiotype antibody 3H1, 10 and the mitogen concanavalin A. After 4 days of incubation in a tissue culture incubator, the cells were pulse -chased with 1 Ci [ 3 H ]thy-]thymidine. Each assay was performed at least in triplicate, and the mean was calculated from samples with SD less than 10%. Stimulation indices were obtained by dividing the mean counts per minute of each sample by the counts per minute obtained using the medium without stimulant.
RESULTS
Cloning of cDNA of 1A7 and the determination of the nucleotide sequence
Total RNA from 1A7 hybridoma cells was used to obtain cDNA encoding the VH and VL chain variable domains of 1A7 by RT-PCR using random mouse IgG primers in a kit from Novagen. Amplified VH and VL DNA fragments were incorporated into pT7Blue( R ) plasmids to obtain pB1A7VH and pB1A7VL (Fig 1) . DNA sequences of the plasmids were determined as described in Materials and Methods. Due to the error -prone nature of Taq polymerase used in these experiments, at least 10 pB1A7VH and pB1A7VL clones were selected for sequencing. Out of 10 clones, seven showed the same sequence, which was accepted as the genuine sequence for 1A7. Amino acid sequences for VH and VL of 1A7 were translated from the corresponding nucleotide sequences and shown in Figure 2 . The predicted amino acid sequences were compared with the N -terminal amino acid sequences of purified 1A7 VH and VL chains to rule out the possibility that the clones originated from other mRNAs present in the 1A7 hybridoma cells. The predicted amino acid sequence showed exact homology as the purified amino acid sequence of the 1A7 VH and VL chains. The leader, framework, and complementarity determining regions were identified by checking the homologies in both the nonredundant Protein Database and the Kabat database 19 in the National Center for Figure 1 . Molecular cloning of 1A7 heavy and light chains and the construction of scFv. Starting plasmids, pB1A7VH and pB1A7VL, were constructed by incorporation of the VH and VL chain fragments of 1A7, respectively, into pT7Blue ( R ) plasmid. VH and VL were joined together using the 15 -amino acid linker as described in Materials and Methods.
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Biotechnology Information Databank using the Blastp program. 20 Various domains of the VH and VL chains are shown in Figure 2 . The 1A7 heavy chain belongs to mouse VH subgroup IB and the light chain belongs to II.
Construction of plasmid vectors encoding single -chain variable regions of 1A7
ScFv consisting of a single VH and VL chain domain is the smallest antibody fragment capable of binding an antigen. 15, 16 In scFv constructs, the carboxy terminus is joined to the amino terminus of variable domains by a Ln of appropriate length and flexibility. Therefore, the scFv can be constructed at least in two different configurations, either VHLnVL or VLLnVH. 15 These two different orientations of domains may distort native conformation of the antigenbinding site of scFv. We have previously shown that for the best antigen mimicry of scFv derived from 3H1 Ð an antiidiotype antibody mimicking carcinoembryonic antigen Ð the VH chain should be in the amino terminus of the scFv; VH and VL should be linked by a 15 -amino acid Ln. 21 To explore the possibility that different configurations of scFv of 1A7 might have different in vitro or in vivo effects, two expression vectors were constructed. In the first one, the VH chain was placed at the amino terminal in the construct ( VHLnVL ) and in the other, it was placed at the carboxy terminal in the construct (VLLnVH ). The strategy for the construction of VHLnVL is presented in Figure 1 . The VLLnVH construct was made by a similar strategy. The expression vectors, pc1A7VHLnVL and pc1A7VLLnVH, Figure 2 . Nucleotide sequences and predicted amino acid sequences of the variable chains of anti -idiotype antibody, 1A7. DNA sequences of the VH ( A ) and VL ( B ) chains of 1A7 were determined as described in Materials and Methods. Various frameworks, complementarity determining regions, and the leader sequences were determined according to Kabat et al. were constructed by incorporation of the scFv cDNAs as described under Materials and Methods and schematically presented in Figure 3 . The plasmids were prepared on a large scale following transformation of DH5-competent cells. To confirm the sequences and orientations of both DNA vaccines, several sets of restriction digestion experiments were conducted. As shown in Figure 4 ( lanes 2 and 3) , digestion of both pc1A7VHLnVL and pc1A7VLLnVH by EcoRV plus XbaI generated a small fragment $800 bp, which was absent in a similar digest of the empty vector, pcDNA ( lane 1) . One KpnI restriction site was present in the VL chain and a second one in the multiple cloning site of pcDNA3 ( Fig 3) . As expected, KpnI digestion of pc1A7VLLnVL generated two fragments of $250 and $5900 bp sizes ( lane 6 ), whereas the pc1A7VHLnVL digest had two bands of sizes $600 and $5600 bp (lane 5) . We concluded from the results of restriction digestion experiments that the plasmids have the desired orientation.
In vitro expression of 1A7 scFv protein by the plasmid vectors
For the DNA vaccines to be effective, it is necessary that 1A7 scFv be transcribed and translated by the eukaryotic machinery. We used the TNT T7 Quick-Coupled Transcription / Translation System to demonstrate the translation of the plasmids in vitro into scFv. SDS -PAGE electrophoresis of metabolically labeled translation products is presented in Figure 5 . A single protein band of $30 kDa was translated using either pc1A7VHLnVL (lane 4 ) or pc1A7VLLnVH ( lane 5 ); however, no radioactive band could be detected using the empty vector, pcDNA3, as the template (lane 1) . Positive control DNA expressing -galactosidase ( lane 2) and luciferase (lane 3 ) was translated into proteins of expected sizes (118 and 61 kDa, respectively ).
The biological activity of expressed 1A7 scFv was evaluated by transient transfection of CHO -KI cells with the plasmids. CHO -KI cells were transfected separately with pc1A7VHLnVL, pc1A7VLLnVH, or pcDNA separately, as described in Materials and Methods. Because leader sequences were incorporated in the 5 H ends of these plasmids, the scFv products synthesized are expected to be released into the culture medium. Transfected cells were cultured in the presence of [
35 S ] L -methionine to label the proteins for 5 hours. The culture supernatants were treated with various antibodies and the labeled products were analyzed by SDS -PAGE electrophoresis as described in Materials and Methods. The results of these experiments are presented in Figure 6 . Treatment with the monoclonal Ab1 antibody, 14G2a, of the supernatant from both pc1A7VHLnVL -and pc1A7VLLnVH -transfected CHO -KI cells resulted in the precipitation of $30-kDa bands (lanes 1 and 7 ) , whereas no such product was present in the supernatant from pcDNAtransfected CHO -KI cells (lane 4 ). No protein band was present when the same supernatant was treated with either a control, isotype-matched murine monoclonal antibody ( lanes 3 and 9 ) , or the monoclonal antibody, 8019 (lanes 2 and 8) , specific for an unrelated anti -idiotype antibody, 3H1. 10 No labeled protein could be detected by treatment of the culture supernatant from pcDNA -transfected CHO -KI cells by any of these antibodies. Taken together, these results demonstrated that the 1A7 scFv translated from the plasmid constructs are recognized by the specific monoclonal Ab1 antibody, 14G2a, and are considered biologically active. Both formats of the plasmids were translated in the eukaryotic CHO -KI cells.
In vivo transcription of scFv of 1A7
To be effective as vaccines, the host cells near the injected sites must take up the DNA and transcribe and translate it to an antigen. The antigen, in turn, must invoke the desired immunity. Most of the injected DNA, however, are likely to be degraded by tissue DNases even before they are taken up inside the host cells. Therefore, it is necessary to demonstrate that the injected plasmids are indeed being taken inside the cells and genes encoding the 1A7 scFv are transcribed and translated into scFv in vivo. Fifty micrograms of pc1A7VLLnVH was injected into the leg quadriceps of C57BL /6 mice. On different days after injection, the injection site was surgically removed, total RNA from the muscle was extracted, and RT-PCR was performed. RT-PCR products in all cases were of the expected size, $800 bp ( Fig 7A ) . To exclude the possibility of plasmid DNA contamination, all RNA samples were treated with DNase I prior to amplification. Moreover, no DNA was detected by direct PCR using 5 H -VL and 3 H -VH primers excluding the possibility of DNA contamination. To further confirm that RT-PCR products represent the VLLnVH DNA fragments of the 1A7 gene, the amplified products were digested with KpnI, and the products were subjected to Southern blot using randomly labeled pc1A7VLLnVH as the probe. Southern blots of the RT-PCR products demonstrated two expected DNA bands of sizes $600 and $200 bp ( Fig 7B ) . Taken together, these results demonstrate that pc1A7VLLnVH is expressed in vivo and the expression lasts for at least 90 days.
Immunohistochemistry of muscle tissue following DNA vaccination
In vitro experiments demonstrated that scFv of 1A7 was expressed and secreted from transiently transfected CHO -K1 cells and that the resulting proteins specifically bound to the monoclonal antibody, 14G2a. To detect the expression of 1A7 scFv in vivo, 50 g of pc1A7VLLnVH was injected into the muscles of the mice. After 7 days, the muscle tissues were excised and immunostained as described under Materials and Methods. The immunostaining results are presented in Figure 8 . Whereas no staining was detected in muscles injected with pcDNA with any of the antibodies ( column II, lanes D ± F ), distinct staining of the muscle cells injected with pc1A7VLLnVH was observed following incubation with the specific monoclonal antibody, 14G2a ( column I, lane C ) . As expected, no staining was detected in pc1A7VLLnVH -injected muscles following incubation with an unrelated monoclonal antibody, 8019, 10 or when the primary antibody was omitted ( column I, lanes B and A, respectively ). CHO -KI cells were transfected with plasmids, pc1A7VHLnVL ( lanes, 4 ± 6 ) or pc1A7VLLnVH ( lanes, 7 ± 9 ) , as described in Materials and Methods. Secreted labeled proteins were precipitated with indicated antibodies, monoclonal anti -1A7 / GD2 antibody, 14G2a, isotype matched unrelated anti -idiotype antibody, 8019, 10 or control isotype matched unrelated antimouse antibody ( anti -IgG ) . The products were analyzed by SDS -PAGE on a 12% gel. We previously demonstrated that injection of 1A7 antiidiotype antibody induced the production of anti -1A7 antibodies in animals 12, 22 as well as in cancer patients. 13 In order to investigate whether plasmids encoding scFv of 1A7 could also induce anti -1A7 antibody production in mice, we injected C57BL /6 mice with pc1A7VHLnVL, pc1A7VLLnVH, and pcDNA3 as described in Materials and Methods. A single immunization, as well as multiple immunizations ( every other week ), was performed with the plasmids. Sera from the mice were drawn before every immunization and the amount of anti -1A7 antibodies was assayed by ELISA as described in Materials and Methods. The results summarized in Figure 9 demonstrate that mice injected with both pc1A7VHLnVL and pc1A7VLLnVH induced the production of anti -1A7 antibodies in the sera of mice, whereas such antibodies are not detectable in mice immunized with pcDNA. A single immunization with pc1A7VLLnVH, without any adjuvant or carrier protein, induced anti -1A7 antibody production; however, multiple immunizations augmented the immune response.
Anti -GD2 antibody response ( Ab1 H response ) of mice immunized with p1A7VHLnVL
To determine whether a clinically relevant Ab1
H immune response was also induced by the DNA vaccines, groups of mice ( three mice per group ) were injected intramuscularly with 50 g of pc1A7VHLnVL. Preimmune sera and sera obtained after four immunizations ( every other week ) were separately pooled for the assay of anti -GD2 by ELISA, as described in Materials and Methods, and the results are presented in Figure 10 . Significant anti -GD2 antibody could be detected in the pooled sera of mice immunized with pc1A7VHLnVL compared to pooled preimmune sera. The binding of the mouse antibodies was maximum with GD2; however, binding with other gangliosides was most likely due to the presence of contaminants in the various ganglioside preparations. This conclusion is supported by the fact Figure 8 . Expression of scFv proteins in the muscles injected with the expression plasmids. pc1A7VLLnVH ( column 1 ) and pcDNA ( column 2 ) were injected into leg quadriceps of C57BL / 6 mice ( 50 g / site ) and after 7 days, the muscle tissues were removed and immunostained with indicated antibodies as described in Materials and Methods. Lanes A, D, no antibody; lanes B, E unrelated isotype matched anti -idiotype antibody, 8019; 10 lanes C, F, 1A7 / GD2 -specific monoclonal antibody, 14G2a. Figure 9 . Induction of anti -1A7 antibodies ( Ab3 response ) in the sera of mice immunized with the expression plasmids. Groups of 6 ± 8 -week -old C57BL / 6 female mice ( n = 8 ± 11 ) were immunized with 100 g of the plasmids once ( day 0 ) or every other week for four times, and sera were drawn at 15 -day intervals. Anti -1A7 antibodies induced in the sera were assayed by ELISA as described in Materials and Methods. Each point represents the mean OD at 405 nm for each group. Figure 10 . Induction of anti -GD2 antibodies ( Ab1 H response ) in the sera of mice immunized with the plasmid expressing 1A7 scFv. Falcon plates ( 96 -well ) were coated with various gangliosides ( 100 ng / well ) and reacted with sera from mice after four immunizations ( every other week ) with p1A7VHLnVL. The sera were diluted 1:10 with PBS ± BSA solution and 100 L of the diluted sera was added per well. Details of the assays are described in Materials and Methods.
that the specific monoclonal anti -GD2 antibody, 14G2a, also reacted with the other gangliosides.
Cellular immune responses by DNA vaccines
DNA vaccines have been shown to induce both cellular and humoral immune responses against a variety of antigens. 14 To determine whether the plasmids expressing 1A7 scFv could induce T-cell responses, spleen proliferation assays were performed as described in Materials and Methods. Proliferation indices with 1A7 as stimulant were similar to indices obtained by using 3H1, the unrelated anti -idiotype antibody (data not shown ). Stimulation indices with concanavalin A as stimulant ranged from 5 -to 10 -fold under the assay conditions.
DISCUSSION
The immunization of mice with plasmids encoding the scFv of the anti -idiotype antibody, 1A7, induced anti -1A7 antibodies in the sera of mice. More importantly, anti -GD2 antibodies by the DNA vaccines are clinically important, as adequate amounts of these antibodies with high avidity are expected to bind to the tumor cell surface GD2 to induce cell lysis. Tumor cell lysis may include antibody -dependent cellular cytotoxicity and complement mediated cytotoxicity.
Levels of anti -GD2 antibodies in mice induced by 1A7VHLnVL were 3 -fold higher than the level in preimmunized mice. This binding, however, was not restricted to GD2, as significant binding to other gangliosides was also observed (Fig 10 ) . This could be due to the presence of contaminants in the ganglioside preparations because specific monoclonal anti-GD2 antibody, 14G2a, also bound to other gangliosides in these experiments ( Fig 10) . An alternative explanation for the binding of these antibodies to other gangliosides could be the close structural similarities of various gangliosides. Another monoclonal anti -GM2 antibody, 3 -207, derived from the transformed lymphocytes from a patient vaccinated with purified GM2 also bound to GD2. 23 Tai et al 24 also obtained a series of antibodies, which showed considerable reactivity to other gangliosides following immunization of mice with purified GD2.
ScFv is the smallest antibody fragment capable of binding an antigen. 16, 25 The scFv can be constructed with either sequence, VHLnVL or VLLnVH. 25 The VHVL construct typically exhibits Euclidean distances between Ln termini of 29 ±35 A Ê , whereas the VL ± VH orientation generally exhibits distances that are 5 ±10 A Ê longer for the same Fv. 26 Thus, differential orientation of a domain may distort the native Fv conformation. An anti-idiotype antibody acts as an antigen intended to induce Ab1 H in the injected host. Distortion of the scFv derived from an anti -idiotype antibody is likely to affect its antigen mimicry. With an anti -idiotype antibody mimicking the carcinoembryonic antigen, we found that only one format, VHLnVL, had biological activity. 21 In the 1A7 system, both formats of scFv expressed by the plasmids had nearly equal biological activities, assayed in vitro as well as in vivo.
Several studies have demonstrated that circular supercoiled plasmid DNA can degrade to an extent, and within 30 ± 90 minutes after injection, more than 95% of the DNA is gone. 27 ± 29 However, plasmid DNA has been also shown to persist for as long as 19 months. 29 We could detect the plasmid for at least 3 months after injection, and during this period, the plasmids were actively transcribed ( Fig 7) . Translation of the plasmid into protein also took place for at least 7 days (Fig 8 ) , a time interval adequate for invoking humoral and cellular immunity in mice.
Incorporation of cytokine genes into DNA vaccines has been demonstrated to augment the immunity induced by the transgene. 30 Co -injection of plasmids expressing cytokines along with DNA vaccines also appears to enhance transgeneinduced immunity. 31 Incorporation of IL -2 or GM -CSF genes into our plasmid, or co-injection of plasmids expressing these cytokines, did not increase the level of expression of 1A7 scFv in the sera of injected mice with these constructs ( data not shown ). DNA encoding secreted proteins has been shown to induce better immune responses than that encoding cell -associated proteins. 32 To augment the immunity of our DNA vaccines, we incorporated the immunoglobulin leader sequences for secretion of the scFv.
Anti -idiotype antibody, 1A7, induced anti -1A7 and anti-GD2 immunity in small animals, 12 nonhuman primates, 22 as well as humans. 13 However, there are several advantages of DNA vaccines over protein antigens. DNA immunization has been shown to enhance dramatically the avidity of the antibody generated compared to soluble proteins. 30 No carrier proteins or adjuvants are necessary for this type of vaccine. In our study, delivery of the plasmids in PBS invoked detectable anti -1A7 scFv antibodies in mice following intramuscular injection. Additional advantages of DNA vaccines over protein antigens are that the plasmids are stable and inexpensive to manufacture in pure form and can be transported at room temperature. Moreover, multiple vaccinations can be safely performed because doublestranded DNAs are non-immunogenic. 31 Most importantly, DNA vaccines have been reported to invoke cellular immune responses in a number of studies. 34 To our disappointment, the preliminary studies using T-cell proliferation assays did not suggest the induction of cellular immune responses by 1A7 anti -idiotype antibody. However, passively administered antibodies as well as vaccine -induced antibodies raised against cell surface antigens, such as gangliosides, have been shown to have antitumor efficacy in animal models as well as in patients ( reviewed in Ref. 35 ). These antibodies are ideal for removal of circulating tumor cells or micrometastases from the bloodstream or lymphatic system, consequently limiting cancer spread. At present, we are evaluating the prophylactic and therapeutic efficacy of our DNA vaccines in a murine lymphoma model (EL -4 ), which constitutively expresses GD2. 36 
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